New hope for rare disease: drug may tame inflammation and cut steroid use

This study tests whether a drug called mepolizumab can help people with a rare disease called EGPA (which causes inflammation in blood vessels, lungs, and sinuses) reach remission better than standard treatments. About 100 adults with active EGPA will receive either mepolizumab or usual care, and doctors will check if they can lower their steroid dose without the disease flaring up. The goal is to find a safer, more effective way to control the disease long-term.